- Home
- PRAX vs CWAN Comparison
PRAX vs CWAN Comparison
Compare PRAX & CWAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRAX | CWAN |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.1B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRAX | CWAN |
|---|---|---|
| Price | $279.95 | $24.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 11 |
| Target Price | ★ $374.64 | $28.85 |
| AVG Volume (30 Days) | 580.3K | ★ 15.4M |
| Earning Date | 02-27-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46826.67 |
| EPS | N/A | ★ 1.40 |
| Revenue | $7,463,000.00 | ★ $640,376,000.00 |
| Revenue This Year | N/A | $64.93 |
| Revenue Next Year | $12,467.71 | $29.40 |
| P/E Ratio | ★ N/A | $17.20 |
| Revenue Growth | ★ 364.98 | 50.91 |
| 52 Week Low | $26.70 | $15.74 |
| 52 Week High | $317.72 | $32.00 |
Technical Indicators
Market Signals| Indicator | PRAX | CWAN |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 71.14 |
| Support Level | $266.93 | $24.05 |
| Resistance Level | $305.21 | $24.19 |
| Average True Range (ATR) | 14.88 | 0.10 |
| MACD | -4.29 | -0.10 |
| Stochastic Oscillator | 27.40 | 25.00 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About CWAN Clearwater Analytics Holdings Inc.
Clearwater Analytics describes its mission as aiming to be the world's most trusted and comprehensive technology platform for the entire investment cycle. Clearwater has historically focused on back-office functions such as investment accounting, but with acquisitions such Enfusion, Beacon, and Bistro, the firm has broadened its focus with front-office and middle-office capabilities. Clearwater primarily serves insurance companies, asset managers, hedge funds, and corporate treasuries. Pro forma for Enfusion, about 76% of Clearwater's revenue is generated in the US.